The Flagship Study: A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The Ship1 Pathway

被引：0
|
作者：
Shrewsbury, S. B. [1 ,2 ]
Bjermer, L. [2 ]
Vestbo, J. [3 ]
Kuna, P. [4 ]
Saarelainen, P. [5 ]
Balint, B. [6 ]
Kalia, V. [1 ]
Tam, P. [1 ]
MacKenzie, L. [1 ]
机构：
[1] Aquinox Pharmaceut Inc, Richmond, BC, Canada
[2] Lund Univ, Lund, Sweden
[3] Univ Southern Denmark, Odense, Denmark
[4] Med Univ Lodz, Barlicki Univ Hosp, Lodz, Poland
[5] Univ Helsinki, Cent Hosp, Helsinki, Finland
[6] Csongrad Megyei Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2889
引用
收藏
页数：1
相关论文
共 38 条
  • [31] Relative Effectiveness of Budesonide/Formoterol and Fluticasone Propionate/Salmeterol in a 1-Year, Population-Based, Matched Cohort Study of Patients With Chronic Obstructive Pulmonary Disease (COPD): Effect on COPD-Related Exacerbations, Emergency Department Visits and Hospitalizations, Medication Utilization, and Treatment Adherence
    Blais, Lucie
    Forget, Amelie
    Ramachandran, Sulabha
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1320 - 1328
  • [32] A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, 12-WEEK STUDY OF THE SAFETY AND EFFICACY OF JZP-110 IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA: SF-36 AND EQ-5D-5L MEASURES
    Benes, H.
    Thein, S. G.
    Andry, J. M., Sr.
    Hudson, J. D.
    Villa, K. F.
    Chen, D.
    Carter, L. P.
    Wang, H.
    Lu, Y.
    Black, J.
    Maynard, J.
    SLEEP, 2017, 40 : A237 - A237
  • [33] A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of avb3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma
    Xu, Jianming
    Niu, Zuoxing
    Bai, Yuxian
    Qiu, Wensheng
    Cui, Jiuwei
    Qu, Xiujuan
    Wu, Zheng
    Zha, Yong
    Zhang, Tao
    Cheng, Wei
    Han, Cuicui
    Si, Meimei
    Li, Lingyan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee
    Cherian, J. J.
    Parvizi, J.
    Bramlet, D.
    Lee, K. H.
    Romness, D. W.
    Mont, M. A.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (12) : 2109 - 2118
  • [35] A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1
    Kwo, P.
    Gitlin, N.
    Nahass, R.
    Bernstein, D.
    Rojter, S.
    Schiff, E.
    Davis, M.
    Ruane, P. J.
    Younes, Z.
    Kalmeijer, R.
    Peeters, M.
    Lenz, O.
    Fevery, B.
    De La Rosa, G.
    Scott, J.
    Sinha, R.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S270 - S270
  • [36] A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2
    Lawitz, E.
    Matusow, G.
    DeJesus, E.
    Yoshida, E.
    Felizarta, F.
    Ghalib, R.
    Godofsky, E.
    Herring, R.
    Poleynard, G.
    Sheikh, A.
    Tobias, H.
    Kugelmas, M.
    Kalmeijer, R.
    Peeters, M.
    Lenz, O.
    Fevery, B.
    De La Rosa, G.
    Scott, J.
    Sinha, R.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S264 - S265
  • [37] Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study (vol 1, pg 51, 2013)
    Vogelmeier, C. F.
    Bateman, E. D.
    Pallante, J.
    LANCET RESPIRATORY MEDICINE, 2013, 1 (02): : 101 - 101
  • [38] Angioedema and angioedema management from ASTERIA II: a phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 antihistamine treatment
    Zazzali, J. L.
    Rosen, K. E.
    Hsieh, H-J
    ALLERGY, 2013, 68 : 43 - 43
1234